Loading patent…
AssigneesNorth Carolina Central University, The University of North Carolina at Chapel Hill, Albert Einstein College of Medicine of Yeshiva University
InventorsMatthew R. Redinbo, Sridhar Mani, Alfred Williams, John Scott, Li-An Yeh, Bret David Wallace, Kimberly Terry Lane
Estimating the term…
Compounds, compositions and methods are provided that comprise selective β-glucuronidase inhibitors for both aerobic and anaerobic bacteria, especially enteric bacteria normally associated with the gastrointestinal tract. The compounds, compositions and methods can be for inhibiting bacterial β-glucuronidases and for improving efficacy of camptothecin-derived antineoplastic agents or glucuronidase-substrate agents or compounds by attenuating the side effects caused by reactivation by bacterial β-glucuronidases of glucuronidated metabolites of camptothecin-derived antineoplastic agents or glucuronidase-substrate agents or compounds.
A composition comprising at least one compound having selective β-glucuronidase inhibitor activity, the compound selected from the group consisting of
A composition comprising at least one compound having selective β-glucuronidase inhibitor activity, the compound selected from the group consisting of
A method for selectively inhibiting bacterial β-glucuronidases, the method comprising administering to a subject in need thereof an effective amount of at least one compound having selective β-glucuronidase inhibitor activity, the compound selected from the group consisting of
A method for improving camptothecin-derived antineoplastic agent efficiency, the method comprising administering to a subject prior to, concurrently with, or after administration of a camptothecin-derived antineoplastic agent a therapeutically effective amount of at least one compound having selective β-glucuronidase inhibitor activity, the compound selected from the group consisting of
A method for alleviating gastrointestinal distress associated with chemotherapy, the method comprising
A method for improving the efficiency of a glucuronidase-substrate agent or compound, the method comprising administering to a subject prior to, concurrently with or after administration of said glucuronidase-substrate agent or compound a therapeutically effective amount of at least one compound having selective β-glucuronidase inhibitor activity, the compound selected from the group consisting of
Dependencies are inferred from the claim text.